Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RHEB | Q15382 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10770981 | 0.86 | KMT2A (0.49) | KMT2ALMNAGAARHEBMAPT | |
| SCHEMBL14920058 | 0.83 | KMT2A (0.46) | KMT2ALMNAGAARHEBMAPT | |
| SCHEMBL11298539 | 0.81 | KMT2A (0.55) | KMT2ALMNAGAARHEBMAPT | |
| SCHEMBL11432939 | 0.79 | RHEB (0.53) | KMT2ARHEBMAPTKDM4EGLA | |
| SCHEMBL7631036 | 0.78 | KMT2A (0.47) | KMT2ALMNAGAARHEBMAPT | |
| SCHEMBL8868635 | 0.74 | LMNA (0.70) | KMT2ALMNAGAATSHRALDH1A1 | |
| SCHEMBL24189619 | 0.74 | LMNA (0.50) | KMT2ALMNAGAATSHRLTA4H | |
| SCHEMBL30397192 | 0.74 | LMNA (0.50) | KMT2ALMNAGAATSHRLTA4H | |
| SCHEMBL7762056 | 0.74 | LMNA (0.50) | KMT2ALMNAGAAMAPTTSHR | |
| SCHEMBL4802709 | 0.73 | RHEB (0.47) | KMT2ARHEBMAPTKDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12318383-B2 | Dual MAGL and FAAH inhibitors | LUNDBECK LA JOLLA RESEARCH CENTER, INC. (US) | 2025-06-03 | — | — | US | disclosed |
| CN-117736178-B | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2025-03-21 | — | — | CN | disclosed |
| EP-4424683-A2 | DUAL MAGL AND FAAH INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3595665-B1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER INC (US) | 2024-08-28 | — | — | EP | disclosed |
| CN-118271288-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117736178-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-03-22 | — | — | CN | disclosed |
| EP-4335848-A2 | DUAL MAGL AND FAAH INHIBITORS | Lundbeck La Jolla Research Center, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| CN-117510468-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-117466868-A | Dual MAGL and FAAH inhibitors | 灵北拉荷亚研究中心公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-110709084-A | Dual MAGL and FAAH inhibitors | 阿比德治疗公司 | 2020-01-17 | — | — | CN | disclosed |
| US-20190282568-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2019-09-19 | — | — | US | disclosed |
| US-20190282568-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2019-09-19 | — | — | US | disclosed |
| US-10350205-B2 | Dual MAGL and FAAH inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10350205-B2 | Dual MAGL and FAAH inhibitors | ABIDE THERAPEUTICS, INC. (US) | 2019-07-16 | — | — | US | disclosed |
| WO-2018169880-A1 | DUAL MAGL AND FAAH INHIBITORS | ABIDE THERAPEUTICS, INC. (US) | 2018-09-20 | — | — | WO | disclosed |
| US-20180256566-A1 | DUAL MAGL AND FAAH INHIBITORS | LUNDBECK LA JOLLA RESEARCH CENTER, INC. | 2018-09-13 | — | — | US | disclosed |
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
| EP-2773613-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064538-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288040-A1 | SUBSTITUTED BENZYLAMINE COMPOUNDS, THEIR USE IN MEDICINE, AND IN PARTICULAR THE TREATMENT OF HEPATITIS C VIRUS (HCV) INFECTION | NR1H4, CFH, SLC10A1 | KMT2A 1852/4885LMNA 1748/4885GAA 4315/4885 |
| US-20250262205-A1 | DUAL MAGL AND FAAH INHIBITORS | FAAH, FAAH2, MAG | KMT2A 2187/4885LMNA 3319/4885GAA 1478/4885 |
| US-12318383-B2 | Dual MAGL and FAAH inhibitors | FAAH, FAAH2, MAG | KMT2A 2187/4885LMNA 3319/4885GAA 1478/4885 |
| US-20190282568-A1 | DUAL MAGL AND FAAH INHIBITORS | FAAH, FAAH2, MAG | KMT2A 2187/4885LMNA 3319/4885GAA 1478/4885 |
| US-10350205-B2 | Dual MAGL and FAAH inhibitors | FAAH, FAAH2, MAG | KMT2A 2187/4885LMNA 3319/4885GAA 1478/4885 |
| US-20180256566-A1 | DUAL MAGL AND FAAH INHIBITORS | FAAH, FAAH2, MAG | KMT2A 2187/4885LMNA 3319/4885GAA 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.